Results 101 to 110 of about 2,626 (203)

Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis:results of the phase 3 ECZTRA 6 trial [PDF]

, 2022
Amoudruz, Petra, Bewley, Anthony, Blauvelt, Andrew, Cork, Michael, Hong, Chih Ho, Imafuku, Shinichi, Kurbasic, Azra, Lophaven, Katja, Paller, Amy, Schuttelaar, Marie L.A., Simpson, Eric L., Soldbro, Lise, Soong, Weily   +12 more
core   +1 more source

Lebrikizumab: a new anti-IL-13 agent for treating moderate-to-severe atopic dermatitis [PDF]

Introduction: Atopic dermatitis (AD) is a common chronic inflammatory skin disease. Moderate-to-severe AD severely affects patients’ quality of life. New drugs selectively targeting molecular pathways involved in the pathogenesis of the disease led to ...
Cataldo Patruno, Caterina Foti, Giampiero Girolomoni, Luca Stingeni, Paolo Amerio, Silvia Ferrucci   +5 more
core   +1 more source

Correction to: Tralokinumab: First Approval [PDF]

Drugs, 2021
openaire   +1 more source

Effectiveness and Safety of Dupilumab and Tralokinumab for Treating Atopic Dermatitis and Pruritic Skin Disorders in Oncological Patients: A Narrative Review

Clinical, Cosmetic and Investigational Dermatology
Giuseppe Lauletta,1 Luca Potestio,1 Cataldo Patruno,2 Mario De Lucia,1 Maddalena Napolitano1 1Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 2Department of Medicine and Health ...
Lauletta G, Potestio L, Patruno C, De Lucia M, Napolitano M   +4 more
doaj  

Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2024

Allergology International
This is an abridged edition of English version of the Clinical Practice Guidelines for the Management of Atopic Dermatitis 2024. Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion.
Hidehisa Saeki, Yukihiro Ohya, Hirokazu Arakawa, Susumu Ichiyama, Toshio Katsunuma, Norito Katoh, Akio Tanaka, Hideaki Tanizaki, Yuichiro Tsunemi, Takeshi Nakahara, Mizuho Nagao, Masami Narita, Michihiro Hide, Takao Fujisawa, Masaki Futamura, Koji Masuda, Tomoyo Matsubara, Hiroyuki Murota, Kiwako Yamamoto-Hanada, Junichi Furuta   +19 more
doaj   +1 more source

Tralokinumab Treatment of Atopic Dermatitis Induces a Progressive Transcriptomic Response

Journal of Investigative Dermatology
Atopic dermatitis (AD) is characterized by a complex epidermal barrier deficiency and exaggerated immune responses dominated by type-2-mechanisms with variable contributions of additional immune axes. Interleukin (IL)-13 is overexpressed in AD skin and a key driver of both barrier dysfunction and inflammation.
Rashmi Tandon, Inken Harder, Dora Stölzl, Matthias Hübenthal, Nicole Sander, Jan Hartmann, Ina Suhrkamp, Melina Fonfara, Sascha Gerdes, Stephan Weidinger   +9 more
openaire   +2 more sources

Long-term Outcomes of New Systemic Agents in Atopic Dermatitis: Drug Survival Analyses and Treatment Patterns in Daily Practice

Acta Dermato-Venereologica
In recent years, several new systemic agents (biologics and Janus kinase inhibitors [JAKi]) have been registered for the treatment of moderate-to-severe atopic dermatitis (AD).
Anne R. Schlosser, Lars Nijman, Renske Schappin, Tamar E.C. Nijsten, Dirkjan Hijnen   +4 more
doaj   +1 more source

Computational drug repositioning through heterogeneous network clustering [PDF]

, 2013

core   +1 more source

Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series [PDF]

The recent approval of novel targeted therapies that included two biologics (dupilumab and tralokinumab) and three small molecules consisting of Janus kinase (JAK) inhibitors (abrocitinib, baricitinib and upadacitinib) has profoundly changed the long-
Andrea Chiricozzi, Angelo Valerio Marzano, Anna Balato, Curdin Conrad, Elena Ippoliti, Flaminia Antonelli, Giampiero Girolomoni, Giulia Coscarella, Giuseppe Argenziano, Jose Manuel Carrascosa, Ketty Peris, Luca Bianchi, Lucia Di Nardo, Marco Galluzzo, Martina Maurelli, Michela Ortoncelli, Monica Munera Campos, Niccolò Gori, Silvia Mariel Ferrucci, Simone Ribero, Teofila Seremet   +20 more
core   +1 more source

Effectiveness of Tralokinumab in Different Phenotypes of Atopic Dermatitis: A Real-World Study

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and a relapsing course, affecting approximately 25% of children and 4–7% of adults. This study evaluated the efficacy, safety, and quality-of-life impact
Ersilia Tolino, Luca Ambrosio, Nicoletta Bernardini, Ilaria Proietti, Nevena Skroza, Concetta Potenza   +5 more
doaj   +1 more source